Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.1M | $146M | $246M | $299M | $490M | $516M | $619M | $611M | $643M |
| Revenue growth | — | 105.8% | 68.1% | 21.5% | 64.1% | 5.3% | 19.8% | -1.3% | 5.2% |
| Gross profit | $60.5M | $118M | $185M | $240M | $416M | $396M | $409M | $414M | $444M |
| Gross margin | 85.1% | 80.4% | 75.2% | 80.4% | 84.9% | 76.7% | 66.2% | 67.9% | 69.1% |
| Operating income | -$18.4M | -$111M | -$30.6M | -$534M | -$52.3M | -$168M | -$265M | -$195M | -$61.0M |
| Operating margin | -25.8% | -75.7% | -12.4% | -178.7% | -10.7% | -32.5% | -42.9% | -31.9% | -9.5% |
| Net income | -$18.8M | -$112M | -$31.3M | -$543M | -$58.2M | -$166M | -$255M | -$183M | -$43.5M |
| Net margin | -26.4% | -76.9% | -12.7% | -181.6% | -11.9% | -32.1% | -41.2% | -29.9% | -6.8% |
| EPS (diluted) | -$1.62 | -$8.40 | -$0.80 | -$5.37 | -$0.53 | -$1.46 | -$2.18 | -$1.52 | -$0.35 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.7M | -$76.4M | $34.6M | -$218M | -$21.4M | -$33.6M | -$15.2M | $6.66M | $136M |
| Capital expenditures | $3.76M | $6.28M | $42.7M | $36.7M | $101M | $132M | $48.6M | $12.4M | $5.93M |
| Free cash flow | -$14.5M | -$82.7M | -$8.12M | -$255M | -$123M | -$165M | -$63.8M | -$5.73M | $130M |
| Share buybacks | $80.0K | — | — | — | — | — | — | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $47.9M | $70.1M | $476M | $689M | $596M | $227M | $359M | $344M | $474M |
| Total assets | — | $124M | $606M | $929M | $1.02B | $1.03B | $965M | $919M | $1.04B |
| Total liabilities | — | $101M | $186M | $190M | $201M | $223M | $224M | $209M | $245M |
| Long-term debt | — | $25.5M | $19.8M | $0.00 | — | — | — | — | — |
| Shareholders' equity | -$113M | -$220M | $420M | $739M | $818M | $806M | $741M | $710M | $796M |
| Retained earnings | — | -$231M | -$262M | -$805M | -$863M | -$1.03B | -$1.28B | -$1.47B | -$1.51B |
| Shares (wtd avg diluted) | — | 14.5M | 39.1M | 101M | 110M | 114M | 117M | 120M | 125M |
Every figure is extracted from 10x Genomics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.